Natixis Vera Therapeutics, Inc. Transaction History
Natixis
- $22 Billion
- Q2 2025
A detailed history of Natixis transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Natixis holds 620 shares of VERA stock, worth $18,259. This represents 0.0% of its overall portfolio holdings.
Number of Shares
620Holding current value
$18,259% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VERA
# of Institutions
202Shares Held
65.3MCall Options Held
1.58MPut Options Held
358K-
Avoro Capital Advisors LLC New York, NY6.3MShares$186 Million2.71% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.48MShares$132 Million0.01% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.43MShares$101 Million9.64% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.35MShares$98.6 Million1.81% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$98.3 Million0.0% of portfolio
About Vera Therapeutics, Inc.
- Ticker VERA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,042,300
- Market Cap $796M
- Description
- Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...